WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services

24 January 2024 | Wednesday | News

WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company specialized in researching, developing and manufacturing innovative therapeutics that improve people's lives worldwide, announced that they have signed a Memorandum of Understanding (MOU) for comprehensive and integrated services which refer to the development, and manufacturing of bioconjugates include antibody-drug conjugates(ADCs).
Image Source : Public Domain

Image Source : Public Domain

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP manufacturing, within the global territory. WuXi XDC will be strategic service partner to support Celltrion's innovative pipeline advances, providing comprehensive services from process development to one-stop GMP manufacturing, aiming to accelerate the development of ADCs at a fast speed and with high quality.

Mr. Jong Moon Cho VP of Celltrion, commented, "Celltrion is focused on fostering the innovation to answer the unmet needs and contribute to the sustainability of healthcare systems. WuXi XDC is an ideal partner for Celltrion given their advanced platform and broad expertise in ADC development and manufacturing. Collaborating with WuXi XDC provides an exciting opportunity for us to further accelerate our innovative pipeline development and benefit patients worldwide." 

Dr. Jimmy Li, CEO of WuXi XDCcommented, "We are very pleased to partner with Celltrion to accelerate their innovative pipeline. With our fully integrated, one-stop platform, we look forward to collaborating with Celltrion to expedite the development and manufacturing for ADC and other bioconjugate candidates. As a global CRDMO, we remain committed to enabling our clients to advance and grow innovative therapeutics at a fast speed and with high quality, and supporting them to achieve the goal of benefiting patients worldwide in the coming years."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in